Anti il-11 antibody
OwnerStuart Cook, Sebastian SCHAEFERinventors
Life of this patent
Estimating the term…
Abstract
The present invention is concerned with improved anti-IL-11 (Interleukin 11) antibodies, isolated nucleotide molecules encoding same, vectors, host cells, compositions, and uses of same.
Claims27
An antibody that binds to human IL-11, the antibody comprising a heavy chain (HC) variable region (VH) sequence and a light chain (LC) variable region (VL) sequence,
- (i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) HC-CDR1 comprising the amino acid sequence GFSLSTSGMV (SEQ ID NO:
- 4) or a variant having one, two or three amino acid substitutions therein,
- (b) HC-CDR2 comprising the amino acid sequence of IDWXGEK wherein ‘X’ is D (SEQ ID NO. 105) or E (SEQ ID NO:
- 123) or a variant having one or two amino acid substitutions therein, and
- (c) HC-CDR3 comprising the amino acid sequence ARSGNYFEY (SEQ ID NO:
- 8) or a variant having one or two amino acid substitutions therein;
- and
- (ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) LC-CDR1 comprising the amino acid sequence EDIYNA (SEQ ID NO:
- 13) or a variant having one or two amino acid substitutions therein,
- (b) LC-CDR2 comprising the amino acid sequence DAN (SEQ ID NO:
- 15) or a variant having one amino acid substitution therein, and
- (c) LC-CDR3 comprising the amino acid sequence QQYYDYPNT (SEQ ID NO:
- 17) or a variant having one or two amino acid substitutions therein.
An antibody that binds to human IL-11, the antibody comprising a heavy chain (HC) variable region sequence and a light chain (LC) variable region sequence,
- (i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) HC-CDR1 comprising the amino acid sequence GYTFTSYV (SEQ ID NO:
- 22) or a variant having one, two or three amino acid substitutions therein,
- (b) HC-CDR2 comprising the amino acid sequence IYPYNDDT (SEQ ID NO:
- 24) or a variant having one or two amino acid substitutions therein, and
- (c) HC-CDR3 comprising the amino acid sequence TRERATYGDLAWFAY (SEQ ID NO:
- 26) or a variant having one or two amino acid substitutions therein;
- and
- (ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) LC-CDR1 comprising the amino acid sequence ENIDSYGNSF (SEQ ID NO:
- 31) or a variant having one or two amino acid substitutions therein,
- (b) LC-CDR2 comprising the amino acid sequence LAS or a variant having one amino acid substitution therein, and
- (c) LC-CDR3 comprising the amino acid sequence QQNNEDPYT (SEQ ID NO:
- 35) or a variant having one or two amino acid substitutions therein, or
- (i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) HC-CDR1 comprising the amino acid sequence GFSLDNYN (SEQ ID NO:
- 40) or a variant having one, two or three amino acid substitutions therein,
- (b) HC-CDR2 comprising the amino acid sequence IWTDGIT (SEQ ID NO:
- 42) or a variant having one or two amino acid substitutions therein, and
- (c) HC-CDR3 comprising the amino acid sequence ARSYYYSLYYFDY (SEQ ID NO:
- 44) or a variant having one or two amino acid substitutions therein;
- and
- (ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) LC-CDR1 comprising the amino acid sequence EDIYSN (SEQ ID NO:
- 49) or a variant having one or two amino acid substitutions therein,
- (b) LC-CDR2 comprising the amino acid sequence DAH or a variant having one amino acid substitution therein, and
- (c) LC-CDR3 comprising the amino acid sequence QQYDNYNT (SEQ ID NO:
- 53) or a variant having one or two amino acid substitutions therein, or
- (i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) HC-CDR1 comprising the amino acid sequence GFSLTNYH (SEQ ID NO:
- 58) or a variant having one, two or three amino acid substitutions therein,
- (b) HC-CDR2 comprising the amino acid sequence MWIDGDT (SEQ ID NO:
- 60) or a variant having one or two amino acid substitutions therein, and
- (c) HC-CDR3 comprising the amino acid sequence AREGLNWFAY (SEQ ID NO:
- 62) or a variant having one or two amino acid substitutions therein;
- and
- (ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) LC-CDR1 comprising the amino acid sequence QGIDDY (SEQ ID NO:
- 67) or a variant having one or two amino acid substitutions therein,
- (b) LC-CDR2 comprising the amino acid sequence DVT or a variant having one amino acid substitution therein, and
- (c) LC-CDR3 comprising the amino acid sequence LQSYSTPYT (SEQ ID NO:
- 71) or a variant having one or two amino acid substitutions therein, or
- (i) the heavy chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) HC-CDR1 comprising the amino acid sequence GFSMSTSGMV (SEQ ID NO:
- 76) or a variant having one, two or three amino acid substitutions therein,
- (b) HC-CDR2 comprising the amino acid sequence IDWDGEK (SEQ ID NO:
- 78) or a variant having one or two amino acid substitutions therein, and
- (c) HC-CDR3 comprising the amino acid sequence ARSGNYFDY (SEQ ID NO:
- 80) or a variant having one or two amino acid substitutions therein;
- and
- (ii) the light chain variable region sequence comprising the CDR3 and at least one additional CDR selected from the group consisting of:
- (a) LC-CDR1 comprising the amino acid sequence EDIYNG (SEQ ID NO:
- 85) or a variant having one or two amino acid substitutions therein,
- (b) LC-CDR2 comprising the amino acid sequence DAN or a variant having one amino acid substitution therein, and
- (c) LC-CDR3 comprising the amino acid sequence QQYYDYPNT (SEQ ID NO:
- 89) or a variant having one or two amino acid substitutions therein.
(canceled)
(canceled)
(canceled)
(canceled)
An antibody that binds to human IL-11, wherein the antibody binds to a discontinuous epitope on human IL-11, wherein the discontinuous epitope comprises amino acid residues:
- (a) R30, S41, T95, R98, S145, and R146;
- (b) R30, S41, R138, R146, R190, K196, T197, and R198;
- (c) R30, T46, R135, S145, R146, R190, and K196;
- (d) S48, T53, R54, R96, R98, S103, R106, H107, T128, R132, R138, R139, H182, and R190;
- or
- (e) T46, T54, T95, R112, H182, and R190;
- when numbered in accordance with SEQ ID NO:
- 125.
26-41. (canceled)
Dependencies are inferred from the claim text.